83732-68-7

Usage

Uses

Used in Pharmaceutical Industry:
2,3-Dichloro-6-methoxypyridine is used as a key intermediate in the synthesis of various pharmaceuticals for its high reactivity and ability to be incorporated into complex drug molecules. Its unique chemical structure allows for the development of new therapeutic agents with potential applications in treating a range of diseases and conditions.
Used in Agrochemical Industry:
2,3-Dichloro-6-methoxypyridine is used as a building block in the production of insecticides and fungicides for its versatility and reactivity. Its incorporation into agricultural chemicals helps in the development of effective pest control solutions, contributing to enhanced crop protection and yield.
Used in Chemical Synthesis:
2,3-Dichloro-6-methoxypyridine is used as a versatile intermediate in various chemical synthesis processes. Its reactivity allows for the formation of a wide range of chemical compounds, making it a valuable component in the development of new materials and products across different industries.

InChI:InChI=1/C6H5Cl2NO/c1-10-5-3-2-4(7)6(8)9-5/h2-3H,1H3

Upstream product

• 742070-73-1 3-chloro-6-methoxypyridin-2-amine 
• 38533-61-8 2-chloro-6-methoxy-3-nitropyridine 
• 17228-64-7 6-chloro-2-methoxypyridine 
• 34392-85-3 3-amino-2-chloro-6-methoxypyridine 

Downstream Products

• 1019849-78-5 1-(3-chloro-6-methoxy-pyridin-2-yl)-3-(R)-methyl-piperazine 
• 24525-63-1 2,3-Dichloro-6-hydroxypyridin 

Relevant academic research and scientific papers

Development of a safe and scalable route towards a tau PET tracer precursor

A scalable 5-step synthesis of the diazacarbazole derivative 1 used as tau PET tracer precursor is reported. Key features of this synthesis include a Buchwald-Hartwig amination, a Pd catalyzed C–H activation and a Suzuki-Miyaura cross-coupling.

COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS

The invention relates to a compound represented by Formula (I): or a pharmaceutically acceptable salt thereof, compositions comprising the same and methods of preparing and using the same. The variables are described herein.

9-AZABICYCLO [3 . 3 . 1] NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS

The present invention relates to a 9-azabicyclo[3.3.1]nonane derivative of formula (I), wherein R1 is H or C1-5alkyl; X is O or NR2, wherein R2 is H, C1-5alkyl or C2-5acyl and Ar is C6-10aryl or a 5-10 membered heteroaryl ring system, both being optionally substituted with one to three of R3-R5 independently selected from halogen, C1-5alkyl, C1-5alkoxy, C3-6cycloalkyl, C2-5alkenyl, C2-5alkynyl, CN, NO2, hydroxy, phenyl, phenoxy and phenylC1-2alkoxy, wherein said C1-5alkyl and C1-5alkoxy are optionally substituted with one to three halogens and wherein said phenyl, phenoxy and phenylC1-2alkoxy are optionally substituted with one to three substituents independently selected from halogen and methyl or two of R3-R5 at adjacent positions together form a methylenedioxy or propylene unit, with the proviso that the compounds exo-9-methyl-3-phenoxy-9-azabicyclo[3.3.1]nonane and N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1H indazole-5-amine are excluded, or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to pharmaceutical compositions comprising said 9-azabicyclo[3.3.1]nonane derivatives and to their use in therapy.

9-Azabicyclo[3.3.1]nonane derivatives

The present invention relates to a 9-azabicyclo[3.3.1]nonane derivative of formula I, wherein each of the substituents is given the definition as set forth in the specification and claims, or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to pharmaceutical compositions comprising said 9-azabicyclo[3.3.1]nonane derivatives and to their use in therapy.

BIARYL PIPERAZINYL-PYRIDINE ANALOGUES

Biaryl piperazinyl -pyri dine analogues are provided, of the Formula (I): wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands, for receptor localization studies.